HIV inhibiting bicyclic pyrimidine derivatives

US10077270B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-10077270-B2
Application numberUS-201715713452-A
CountryUS
Kind codeB2
Filing dateSep 22, 2017
Priority dateOct 29, 2004
Publication dateSep 18, 2018
Grant dateSep 18, 2018

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

HIV replication inhibitors of formula wherein -a 1 =a 2 -a 3 =a 4 - is —CH═CH—CH═CH—, —N═CH—CH═CH—, —N═CH—N═CH—, —N═CH—CH═N—, —N═N—CH═CH—; -b 1 =b 2 -b 3 =b 4 - is —CH═CH—CH═CH—, —N═CH—CH═CH—, —N═CH—N═CH—, —N═CH—CH═N—, —N═N—CH═CH—; n and m is 0-4, R 1 is hydrogen; aryl; formyl; C 1-6 alkylcarbonyl; C 1-6 alkyl; C 1-6 alkyloxycarbonyl; R 2 is OH; halo; C 1-6 alkyl, C 2-6 alkenyl or C 2-6 alkynyl; substituted carbonyl; carboxyl; CN; nitro; amino; polyhalomethyl; polyhalomethylthio; —S(═O) p R 6 ; C(═NH)R 6 ; R 2a is CN; amino; substituted amino; C 1-6 alkyl; halo; C 1-6 alkyloxy; carbonyl; —CH═N—NH—C(═O)—R 16 ; C 1-6 alkyloxyC 1-6 alkyl; C 2-6 alkenyl or C 2-6 alkynyl; —C(═N—O—R 8 )—C 1-4 alkyl; R 7 or —X—R 7 ; R 3 is CN; amino; C 1-6 alkyl; halo; C 1-6 alkyloxy; substituted carbonyl; —CH═N—NH—C(═O)—R 16 ; substituted C 1-6 alkyl; C 1-6 alkyloxyC 1-6 alkyl; substituted C 2-6 alkenyl or C 2-6 alkynyl; —C(═N—O—R 8 )—C 1-4 alkyl; R 7 ; —X—R 7 ; R 4 is halo; OH; C 1-6 alkyl, C 2-6 alkenyl or C 2-6 alkynyl; C 3-7 cycloalkyl; C 1-6 alkyloxy; CN; nitro; polyhaloC 1-6 alkyl; polyhaloC 1-6 alkyloxy; substituted carbonyl; formyl; amino; mono- or di(C 1-4 alkyl)amino or R 7 ; -A-B— is —CR 5 ═N—, —N═N—, —CH 2 —CH 2 —, —CS—NH—, —CO—NH—, —CH═CH—; and the use of these compounds for the prevention or the treatment of HIV infection.

First claim

Opening claim text (preview).

The invention claimed is: 1. A compound of formula a N-oxide; a pharmaceutically acceptable addition salt; a quaternary amine; or a stereochemically isomeric form thereof, wherein -a 1 =a 2 -a 3 =a 4 - represents a bivalent radical of a formula selected from the group consisting of: —CH═CH—CH═CH—  (a-1); —N═CH—CH═CH—  (a-2); —N═CH—N═CH—  (a-3); —N═CH—CH═N—  (a-4); and —N═N—CH═CH—  (a-5); -b 1 =b 2 -b 3 =b 4 - represents a bivalent radical of a formula selected from the group consisting of: —CH═CH—CH═CH—  (b-1); —N═CH—CH═CH—  (b-2); —N═CH—N═CH—  (b-3); —N═CH—CH═N—  (b-4); and —N═N—CH═CH—  (b-5); n is 0, 1, 2, 3 and in case -a 1 =a 2 -a 3 =a 4 - is (a-1), then n may also be 4; m is 0, 1, 2, 3 and in case -b 1 =b 2 -b 3 =b 4 - is (b-1), then m may also be 4; -A-B— represents a bivalent radical of a formula: —CS—NH—; R 1 is a member selected from the group consisting of: hydrogen; aryl; formyl; C 1-6 alkylcarbonyl; C 1-6 alkyl; C 1-6 alkyloxycarbonyl; and C 1-6 alkyl substituted with a member selected from the group consisting of: formyl, C 1-6 alkylcarbonyl, and C 1-6 alkyloxycarbonyl; each R 2 independently is selected from the group consisting of: hydroxy; halo; C 1-6 alkyl optionally substituted with one, two or three substituents each independently selected from halo, cyano and —C(═O)R 6 ; C 3-7 cycloalkyl; C 2-6 alkenyl optionally substituted with one, two or three substituents each independently selected from halo, cyano and —C(═O)R 6 ; C 2-6 alkynyl optionally substituted with one, two or three substituents each independently selected from halo, cyano and —C(═O)R 6 ; C 1-6 alkyloxycarbonyl; carboxyl; cyano; nitro; amino; mono- or di(C 1-6 alkyl)amino; polyhalomethyl; polyhalomethylthio; —S(═O) p R 6 ; —NH—S(═O) p R 6 ; —C(═O)R 6 ; —NHC(═O)H; —C(═O)NHNH 2 ; NHC(═O)R 6 ; and C(═NH)R 6 ; R 2a is a member selected from the group consisting of: cyano; aminocarbonyl; amino; C 1-6 alkyl; halo; C 1-6 alkyloxy wherein the C 1-6 alkyl moiety of the C 1-6 alkyloxy may optionally be substituted with cyano; NHR 13 ; NR 13 R 14 ; —C(═O)—NHR 13 ; —C(═O)—NR 13 R 14 ; C(═O)—R 15 ; —CH═N—NH—C(═O)—R 16 ; C 1-6 alkyl substituted with one, two or three substituents each independently selected from halo, cyano, NR 9 R 10 , —C(═O)—NR 9 R 10 , —C(═O)—C 1-6 alkyl and R 7 ; C 1-6 alkyl substituted with hydroxy and a second substituent selected from halo, cyano, NR 9 R 10 , —C(═O)—NR 9 R 10 , —C(═O)—C 1-6 alkyl and R 7 ; C 1-6 alkyloxyC 1-6 alkyl optionally substituted with one, two or three substituents each independently selected from halo, cyano, NR 9 R 10 , —C(═O)—NR 9 R 10 , —C(═O)—C 1-6 alkyl and R 7 ; C 2-6 alkenyl substituted with one, two or three substituents each independently selected from halo, cyano, NR 9 R 10 , —C(═O)—NR 9 R 10 , —C(═O)—C 1-6 alkyl and R 7 ; C 2-6 alkynyl substituted with one, two or three substituents each independently selected from halo, cyano, NR 9 R 10 , —C(═O)—NR 9 R 10 , —C(═O)—C 1-6 alkyl and R 7 ; —C(═N—O—R 8 )—C 1-4 alkyl; R 7 ; and —X—R 7 ; R 3 is a member selected from the group consisting of: cyano; aminocarbonyl; amino; C 1-6 alkyl; halo; C 1-6 alkyloxy wherein the C 1-6 alkyl moiety of the C 1-6 alkyloxy may optionally be substituted with cyano; NHR 13 ; NR 13 R 14 ; —C(═O)—NHR 13 ; —C(═O)—NR 13 R 14 ; —C(═O)—R 15 ; —CH═N—NH—C(═O)—R 16 ; C 1-6 alkyl substituted with one, two or three substituents each independently selected from halo, cyano, NR 9 R 10 , —C(═O)—NR 9 R 10 , —C(═O)—C 1-6 alkyl and R 7 ; C 1-6 alkyl substituted with hydroxy and a second substituent selected from halo, cyano, NR 9 R 10 , —C(═O)—NR 9 R 10 , —C(═O)—C 1-6 alkyl and R 7 ; C 1-6 alkyloxyC 1-6 alkyl optionally substituted with one, two or three substituents each independently selected from halo, cyano, NR 9 R 10 , —C(═O)—NR 9 R 10 , —C(═O)—C 1-6 alkyl and R 7 ; C 2-6 alkenyl substituted with one, two or three substituents each independently selected from halo, cyano, NR 9 R 10 , —C(═O)—NR 9 R 10 , —C(═O)—C 1-6 alkyl and R 7 ; C 2-6 alkynyl substituted with one, two or three substituents each independently selected from halo, cyano, NR 9 R 10 , —C(═O)—NR 9 R 10 , —C(═O)—C 1-6 alkyl and R 7 ; —C(═N—O—R 8 )—C 1-4 alkyl; R 7 ; and —X—R 7 ; X is a member selected from the group consisting of: —NR 1 —, —O—, —C(═O)—, —S—, and —S(═O) p —; each R 4 independently is a member selected from the group consisting of: halo; hydroxy; C 1-6 alkyl optionally substituted with one, two or three substituents each independently selected from halo, cyano and —C(═O)R 6 ; C 2-6 alkenyl optionally substituted with one, two or three substituents each independently selected from halo, cyano and —C(═O)R 6 ; C 2-6 alkynyl optionally substituted with one, two or three substituents each independently selected from halo, cyano and —C(═O)R 6 ; C 3-7 cycloalkyl; C 1-6 alkyloxy; cyano; nitro; polyhaloC 1-6 alkyl; polyhaloC 1-6 alkyloxy; aminocarbonyl; mono- or di(C 1-4 alkyl)aminocarbonyl; C 1-6 alkyloxycarbonyl; C 1-6 alkylcarbonyl; formyl; amino; mono- or di(C 1-4 alkyl)amino; and R 7 ; Q is a member selected from the group consisting of: hydrogen, C 1-6 alkyl, halo, polyhaloC 1-6 alkyl, and —NR 9 R 10 ; R 6 is a member selected from the group consisting of: C 1-4 alkyl, amino, mono- or di(C 1-4 alkyl)amino, and polyhaloC 1-4 alkyl; R 7 is a member selected from the group consisting of: a monocyclic, bicyclic or tricyclic saturated, partially saturated or aromatic carbocycle; or a monocyclic, bicyclic or tricyclic saturated, partially saturated or aromatic heterocycle; wherein each of said carbocyclic or heterocyclic ring systems may optionally be substituted with one, two, three, four or five substituents each independently selected from the group consisting of: halo, hydroxy, mercapto, C 1-6 alkyl, hydroxy C 1-6 alkyl, aminoC 1-6 alkyl, mono and di(C 1-6 alkyl)aminoC 1-6 alkyl, formyl, C 1-6 alkylcarbonyl, C 3-7 cycloalkyl, C 1-6 alkyloxy, C 1-6 alkyloxycarbonyl, C 1-6 alkylthio, cyano, nitro, polyhaloC 1-6 alkyl, polyhaloC 1-6 alkyloxy, aminocarbonyl, —CH(═N—O—R 8 ), R 7a , —X—R 7a and R 7a —C 1-4 alkyl; R 7a is a member selected from the group consisting of: a monocyclic, bicyclic or tricyclic saturated, partially saturated or aromatic carbocycle; or a monocyclic, bicyclic or tricyclic saturated, partially saturated or aromatic heterocycle; wherein each of said carbocyclic or heterocyclic ring systems may optionally be substituted with one, two, three, four or five substituents each independently selected from the group consisting of: halo, hydroxy, mercapto, C 1-6 alkyl, hydroxyC 1-6 alkyl, aminoC 1-6 alkyl, mono or di(C 1-6 alkyl)amino C 1-6 alkyl, formyl, C 1-6 alkylcarbonyl, C 3-7 cycloalkyl, C 1-6 alkyloxy, C 1-6 alkyloxycarbonyl, C 1-6 alkylthio, cyano, nitro, polyhaloC 1-6 alkyl, polyhaloC 1-6 alkyloxy, aminocarbonyl, and —CH(═N—O—R 8 ); R 8 is a member selected from the group consisting of: hydrogen, C 1-4 alkyl, aryl or arylC 1-4 alkyl; R 9 and R 10 each independently are a member selected from the group consisting of: hydrogen; hydroxy; C 1-6 alkyl; C 1-6 alkyloxy; C 1-6 alkylcarbonyl; C 1-6 alkyloxycarbonyl; amino; mono- or di(C 1-6 alkyl)amino; mono- or di(C 1-6 alkyl)aminocarbonyl; —CH(═NR 11 ) and R 7 wherein each of the aforementioned C 1-6 alkyl groups may optionally and each individually be substituted with one or two substituents each independently selected from the group consisting of: hydroxy, C 1-6 alkyloxy, hydroxyC 1-4 alkyloxy, carboxyl, C 1-6 alkyloxycarbonyl, cyano, amino, imino, mono- or di(C 1-4 alkyl)amino, polyhalomethyl, polyhalomethyloxy, polyhalomethylthio, —S(═O) p R 6 , —NH—S(═O) p R 6 , —C(═O)R 6 ,

Assignees

Inventors

Classifications

  • two nitrogen atoms · CPC title

  • C07D487/04Primary

    Ortho-condensed systems · CPC title

  • one nitrogen and one sulfur atom · CPC title

  • Heterocyclic compounds containing purine ring systems · CPC title

  • for HIV · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US10077270B2 cover?
HIV replication inhibitors of formula wherein -a 1 =a 2 -a 3 =a 4 - is —CH═CH—CH═CH—, —N═CH—CH═CH—, —N═CH—N═CH—, —N═CH—CH═N—, —N═N—CH═CH—; -b 1 =b 2 -b 3 =b 4 - is —CH═CH—CH═CH—, —N═CH—CH═CH—, —N═CH—N═CH—, —N═CH—CH═N—, —N═N—CH═CH—; n and m is 0-4, R 1 is hydrogen; aryl; formyl; C 1-6 alkylcarbonyl; C 1-6 alkyl; C 1-6 alkyloxycarbonyl; R 2 is OH; halo; C 1…
Who is the assignee on this patent?
Janssen Sciences Ireland Uc
What technology area does this patent fall under?
Primary CPC classification C07D487/04. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Sep 18 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).